Brazil Cancer Drugs Market Clinical Trials Report 2024: Brazil Emerges as a Leading Force in Cancer Drug Clinical Trials
Brazil emerges as a key hub for oncology clinical trials, with Roche leading in trials for drugs like Atezolizumab and Pertuzumab. NSCLC trials dominate, reflecting high lung cancer rates. Phase III trials prevail, supported by CROs, indicating Brazil's role in late-stage cancer treatment development.
Reference News
Brazil emerges as a key hub for oncology clinical trials, with Roche leading in trials for drugs like Atezolizumab and Pertuzumab. The country focuses on prevalent cancers, with NSCLC trials dominating. Phase III trials are prevalent, supported by CROs, indicating Brazil's role in global cancer research.
Brazil emerges as a key hub for oncology clinical trials, with Roche leading in trials for drugs like Atezolizumab and Pertuzumab. NSCLC trials dominate, reflecting high lung cancer rates. Phase III trials prevail, supported by CROs, indicating Brazil's role in late-stage cancer treatment development.